Special Care Issues of Women Living with HIV-AIDS

Infectious Disease Clinics of North America

Volumn 21, Issue 1, 2007, Pages 133-148

  Kojic, Erna Milunka ^a   Cu Uvin, Susan ^b  

^a MIRIAM HOSPITAL   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VALACICLOVIR; WART VIRUS VACCINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE TRANSMISSION; GENITAL TRACT INFECTION; HEALTH CARE PERSONNEL; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; MENOPAUSE; MENSTRUAL CYCLE; META ANALYSIS; MONOTHERAPY; PATIENT CARE; PREGNANCY; PREVALENCE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; UNITED STATES; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONTRACEPTION; FEMALE; HIV INFECTIONS; HUMANS; MENOPAUSE; MENSTRUAL CYCLE; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; REPRODUCTION; RISK FACTORS; WOMEN'S HEALTH; WORLD HEALTH;

EID: 34248383163     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.01.004     Document Type: Review

References (98)

1. CDC. Cases of HIV infection and AIDS in the United States, 2004. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2004report. Accessed November 15, 2006.
2. UNAIDS. Global coalition on women and AIDS. Available at: http://womenandaids.org. Accessed November 15, 2006.
3. Greenblatt R.M., Lukehart S.A., Plummer F.A., et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 2 1 (1988) 47-50
4. Plummer F.A., Simonsen J.N., Cameron D.W., et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 163 2 (1991) 233-239
5. Wasserheit J.N. Epidemiological synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 19 2 (1992) 61-77
6. Cu-Uvin S., Hogan J.W., Warren D., et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis 29 5 (1999) 1145-1150
7. Strick L.B., Wald A., and Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 43 3 (2006) 347-356
8. Sobel J.D. Gynecologic infections in human immunodeficiency virus-infected women. Clin Infect Dis 31 5 (2000) 1225-1233
9. Posavad C.M., Wald A., Kuntz S., et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 190 4 (2004) 693-696
10. Ioannidis J.P., Collier A.C., Cooper D.A., et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 178 2 (1998) 349-359
11. Cu-Uvin S., Hogan J.W., Caliendo A.M., et al. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis 33 6 (2001) 894-896
12. Ho G.Y., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 7 (1998) 423-428
13. Jamieson D.J., Duerr A., Burk R., et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 186 1 (2002) 21-27
14. Palefsky J.M., Minkoff H., Kalish L.A., et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 91 3 (1999) 226-236
15. Sun X.W., Kuhn L., Ellerbrock T.V., et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337 19 (1997) 1343-1349
16. Ellerbrock T.V., Chiasson M.A., Bush T.J., et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 283 8 (2000) 1031-1037
17. Massad L.S., Riester K.A., Anastos K.M., et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr 21 1 (1999) 33-41
18. Minkoff H., Ahdieh L., Massad L.S., et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 15 16 (2001) 2157-2164
19. de Sanjose S., and Palefsky J. Cervical and anal HPV infections in HIV positive women and men. Virus Res 89 2 (2002) 201-211
20. Piketty C., and Kazatchkine M.D. Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Curr HIV/AIDS Rep 2 3 (2005) 140-145
21. Palefsky J.M., Holly E.A., Ralston M.L., et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 183 3 (2001) 383-391
22. Holly E.A., Ralston M.L., Darragh T.M., et al. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 93 11 (2001) 843-849
23. Kojic EM, Cu-Uvin S, Conley L, et al. Human papilloma virus (HPV) infection of the anus is more prevalent and diverse than HPV infection of the cervix among HIV-Infected Women in the SUN Study. Presented at the Infectious Disease Society of America 44th Annual Meeting. Toronto (Canada), October 12-15, 2006.
24. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
25. Chirgwin K.D., Feldman J., Muneyyirci-Delale O., et al. Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 12 5 (1996) 489-494
26. Clark R.A., Mulligan K., Stamenovic E., et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis 184 10 (2001) 1325-1327
27. Ellerbrock T.V., Wright T.C., Bush T.J., et al. Characteristics of menstruation in women infected with human immunodeficiency virus. Obstet Gynecol 87 6 (1996) 1030-1034
28. Harlow S.D., Schuman P., Cohen M., et al. Effect of HIV infection on menstrual cycle length. J Acquir Immune Defic Syndr 24 1 (2000) 68-75
29. Harlow S.D., Cohen M., Ohmit S.E., et al. Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus. Am J Obstet Gynecol 188 4 (2003) 881-886
30. Massad L.S., Evans C.T., Minkoff H., et al. Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women. J Womens Health (Larchmt) 15 5 (2006) 591-598
31. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 28 12 (2005) 1075-1083
32. Cohn SE, Watts DH, Lertora J, et al. An open-label, non-randomized study of the effect of depo-medroxyprogesterone acetate on the pharmacokinetics (PK) of selected protease inhibitors and non-nucleoside reverse transcriptase inhibitors therapies among HIV-infected women. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Hynes Convection Center, Boston (MA), February 22-25, 2005.
33. Morrison C.S., Sekadde-Kigondu C., Sinei S.K., et al. Is the intrauterine device appropriate contraception for HIV-1-infected women?. BJOG 108 8 (2001) 784-790
34. Richardson B.A., Morrison C.S., Sekadde-Kigondu C., et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 13 15 (1999) 2091-2097
35. Sivin I., and Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 61 1 (1994) 70-77
36. Cooper E.R., Charurat M., Mofenson L., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29 5 (2002) 484-494
37. Chen J.L., Philips K.A., Kanouse D.E., et al. Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect 33 4 (2001) 144-152 165
38. Chu S.Y., Hanson D.L., and Jones J.L. Pregnancy rates among women infected with human immunodeficiency virus. Adult/Adolescent HIV Spectrum of Disease Project Group. Obstet Gynecol 87 2 (1996) 195-198
39. Massad L.S., Springer G., Jacobson L., et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS 18 2 (2004) 281-286
40. Fabiani M., Nattabi B., Ayella E.O., et al. Differences in fertility by HIV serostatus and adjusted HIV prevalence data from an antenatal clinic in northern Uganda. Trop Med Int Health 11 2 (2006) 182-187
41. Ross A., Van der Paal L., Lubega R., et al. HIV-1 disease progression and fertility: the incidence of recognized pregnancy and pregnancy outcome in Uganda. AIDS 18 5 (2004) 799-804
42. Sedgh G., Larsen U., Spiegelman D., et al. HIV-1 disease progression and fertility in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 39 4 (2005) 439-445
43. Stephenson J.M., and Griffioen A. The effect of HIV diagnosis on reproductive experience. Study Group for the Medical Research Council Collaborative Study of Women with HIV. AIDS 10 14 (1996) 1683-1687
44. Mofenson L.M. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 421 (1997) 1-9
45. Coutsoudis A., Dabis F., Fawzi W., et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 189 12 (2004) 2154-2166
46. Fawzi W.W., Msamanga G.I., Spiegelman D., et al. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet 351 9114 (1998) 1477-1482
47. Garcia P.M., Kalish L.A., Pitt J., et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 341 6 (1999) 394-402
48. Landesman S.H., Kalish L.A., Burns D.N., et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med 334 25 (1996) 1617-1623
49. Mofenson L.M., Lambert J.S., Stiehm E.R., et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 341 6 (1999) 385-393
50. Minkoff H., and Mofenson L.M. The role of obstetric interventions in the prevention of pediatric human immunodeficiency virus infection. Am J Obstet Gynecol 171 5 (1994) 1167-1175
51. Groginsky E., Bowdler N., and Yankowitz J. Update on vertical HIV transmission. J Reprod Med 43 8 (1998) 637-646
52. Minkoff H.L. HIV disease in pregnancy. Introduction. Obstet Gynecol Clin North Am 24 4 (1997) xi-xvii
53. Reinhardt P.P., Reinhardt B., Lathey J.L., et al. Human cord blood mononuclear cells are preferentially infected by non-syncytium-inducing, macrophage-tropic human immunodeficiency virus type 1 isolates. J Clin Microbiol 33 2 (1995) 292-297
54. De Pasquale M.P., Leigh Brown A.J., Uvin S.C., et al. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 34 1 (2003) 37-44
55. Rasheed S., Li Z., Xu D., et al. Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet Gynecol 175 1 (1996) 122-129
56. Alliegro M.B., Dorrucci M., Phillips A.N., et al. Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group. Arch Intern Med 157 22 (1997) 2585-2590
57. French R., and Brocklehurst P. The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 105 8 (1998) 827-835
58. Minkoff H., Hershow R., Watts D.H., et al. The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol 189 2 (2003) 552-559
59. Cao Y., Krogstad P., Korber B.T., et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 3 5 (1997) 549-552
60. Watts D.H., Lambert J., Stiehm E.R., et al. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 33 5 (2003) 585-593
61. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331 18 (1994) 1173-1180
62. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States - October 12, 2006. Available at: http://aidsinfo.nih.gov. Accessed November 14, 2006.
63. Petra Study. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 359 (2002) 1178-1186
64. Shaffer N., Chuachoowong R., Mock P.A., et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 353 9155 (1999) 773-780
65. Juethner S.N., Williamson C., Ristig M.B., et al. Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr 32 2 (2003) 153-156
66. Palumbo P., Holland B., Dobbs T., et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 184 9 (2001) 1120-1126
67. Eshleman S.H., Hoover D.R., Chen S., et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 192 1 (2005) 30-36
68. Eshleman S.H., Mracna M., Guay L.A., et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15 15 (2001) 1951-1957
69. Johnson J.A., Li J.F., Morris L., et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 192 1 (2005) 16-23
70. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. N Engl J Med 340 13 (1999) 977-987
71. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration. Lancet 353 9158 (1999) 1035-1039
72. The European Collaborative Study and the Swiss Mother Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 14 18 (2000) 2913-2920
73. Tuomala R.E., Shapiro D.E., Mofenson L.M., et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 346 24 (2002) 1863-1870
74. Barret B., Tardieu M., Rustin P., et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 17 12 (2003) 1769-1785
75. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 25 (2000) 261-268
76. De Santis M., Carducci B., De Santis L., et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 162 3 (2002) 355
77. Available at: http://www.apregistry.com/.
78. Hitti J., Frenkel L.M., Stek A.M., et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 36 3 (2004) 772-776
79. Lyons F., Hopkins S., Kelleher B., et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 7 4 (2006) 255-260
80. Stern J.O., Robinson P.A., Love J., et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 34 Suppl 1 (2003) S21-S33
81. Available at: http://www.fda.gov/medWatch/SAFETY/2001/pregwarnfinalBMS.pdf.
82. Dube M.P., and Sattler F.R. Metabolic complications of antiretroviral therapies. AIDS Clin Care 10 6 (1998) 41-44
83. Suy A., Martinez E., Coll O., et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 20 1 (2006) 59-66
84. Paoletti R., and Wenger N.K. Review of the international position paper on women's health and menopause: a comprehensive approach. Circulation 107 9 (2003) 1336-1339
85. van Benthem B.H., Vernazza P., Coutinho R.A., et al. The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women. AIDS 16 6 (2002) 919-924
86. Kalayjian R.C., Landay A., Pollard R.B., et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis 187 12 (2003) 1924-1933
87. Viard J.P., Mocroft A., Chiesi A., et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 183 8 (2001) 1290-1294
88. Manfredi R., Calza L., Cocchi D., et al. Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr 33 1 (2003) 112-114
89. Tumbarello M., Rabagliati R., De Gaetano Donati K., et al. Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS 17 1 (2003) 128-131
90. Safadi F.F., Dissanayake I.R., Goodman G.G., et al. Influence of estrogen deficiency and replacement on T-cell populations in rat lymphoid tissues and organs. Endocrine 12 1 (2000) 81-88
91. McKinlay S.M., Bifano N.L., and McKinlay J.B. Smoking and age at menopause in women. Ann Intern Med 103 3 (1985) 350-356
92. Cejtin H, Kim S, Taylor T, et al. Menopause in women in the Women's Interagency HIV Study (WIHS). Presented at the XV International AIDS Conference. Bangkok (Thailand), July 11-16, 2004.
93. Schoenbaum E.E., Hartel D., Lo Y., et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 41 10 (2005) 1517-1524
94. van Asselt K.M., Kok H.S., van Der Schouw Y.T., et al. Current smoking at menopause rather than duration determines the onset of natural menopause. Epidemiology 15 5 (2004) 634-639
95. Wanke C.A., Silva M., Knox T.A., et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31 3 (2000) 803-805
96. Cejtin H, Kim S, Taylor T, et al. Assessment of menopausal status among women in the Women's Interagency HIV Study (WIHS). Presented at the XV International AIDS Conference. Bangkok (Thailand), July 11-16, 2004.
97. Clark R.A., Cohn S.E., Jarek C., et al. Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr 23 1 (2000) 99-100
98. Bosworth H.B., Bastian L.A., Kuchibhatla M.N., et al. Depressive symptoms, menopausal status, and climacteric symptoms in women at midlife. Psychosom Med 63 4 (2001) 603-608